Guwahati: The first quarter of 2023 will mark the beginning of the Serum Institute of India’s (SII) production of the quadrivalent Human Papillomavirus (HPV) “CERVAVAC” vaccine which was delayed because to the COVID-19 pandemic said SII CEO Adar Poonawalla on Friday.
The “CERVAVAC” vaccine which was created locally has been announced to prevent cervical cancer.
“The capacity got delayed by one year because we are using a new building to this. We use the original HPV vaccine building for Covovax. So, we have to, at that time, had no choice during the pandemic and you know, there are many vaccines like dengue and so many other developments that were deferred by two years for this,” Poonawalla said.
On the export of HPV vaccines to other countries he said, “We have already submitted the files and once that is done, we can then export in 2024 to UNICEF, Gavi and the African countries also because there was a shortage of HPV vaccine for the last few years.”
He added that the vaccine already has a licence from India’s Drugs Controller General (DCGI).
“We will scale up beyond that to reach about 150 million doses or so because eventually I think the Indian immunisation programme will also take a substantial amount and that will also take time to scale up. So, we are matching our scale-up with the demand to satisfy India and its requirements. We are just one year later than what I would have wanted to be in terms of our capacity. We are already licensed by the DCGI,” he said.
The CEO of SII also stated that the government will receive one or two million doses of the HPV vaccine each month while speaking about its manufacture in 2023.
“We will be making a very small quantity and launching it in the Indian government programme in first quarter of next year and followed by having a capacity of 70 million doses which can go up to 150 to 200 million doses the year after that, so to be clear, in 2023, will have a capacity of maybe around 20 million doses. So that’s about one or 2 million doses per month that will be supplied to the government followed by which we will get it who requalification hopefully with all the data that will present,” said Adar Poonawalla on production of HPV vaccine in 2023.
Earlier, Adar Poonawalla said that HPV vaccine will be available at an affordable price, “We will announce the price in a few months, it’ll be approx Rs 200-400. We will finalise after manufacturing and discussion with the Government of India.”
As the first indigenously created vaccine in India, “CERVAVAC,” was announced for the prevention of cervical cancer Union Minister Dr. Jitendra Singh was present.
“India has come out with the first indigenously developed vaccine for cervical cancer, prevalent among women of the younger age group. Thanks to PM we can now afford to look for preventive healthcare. This vaccine will be affordable,” said Singh.
‘CERVAVAC’ is an outcome of a partnership of DBT and BIRAC with the Bill and Melinda Gates Foundation, supported by Serum Institute of India Private Limited for the indigenous development of quadrivalent vaccine through its partnership programme ‘Grand Challenges India’.